Author Archives: Patricia Inacio, PhD

#EULAR 2016 – Drug for Children and Teens with Lupus Shows Promise in Early Study

The Alliance for Children’s Therapeutics presented positive results from an early study of KPI Therapeutics/Kineta’s lead drug candidate, dalazatide, as a possible treatment for children and teenagers with lupus nephritis. The data were given at the recent European League Against Rheumatism’s 17th Annual Congress in London. A key finding was that “patients with…

Lupus Patients’ Molecular Signature May Allow for Personalized Therapies, Scientists Say

Immuno-molecular profiling of systemic lupus erythematosus (SLE) patients has uncovered a personalized molecular signature underlying disease activity that may help scientists develop new tailored therapeutics. The study, “Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients,” was recently published in the journal Cell. SLE, which predominantly affects young women, is…

Intestinal Dysbiosis Promotes Pro-inflammatory Environment in SLE Patients

In systemic lupus erythematosus (SLE) patients, intestinal dysbiosis is associated with activation of pro-inflammatory cells. As such, rescuing gut microbiota with beneficial bacteria strains improves patients’ inflammatory profile, according to a study entitled “Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients”…

PAH an Important Prognostic Factor in Lupus Patients, According to Review

Pulmonary arterial hypertension (PAH) is a prevalent comorbid factor in systemic lupus erythematosus (SLE) patients, significantly increasing mortality outcomes. This is the conclusion of a recent review titled “Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis,” published in the journal…

In Lupus, Natural Killer Cells May Play a Protective Role

In a review titled “Immunoregulation of NKT Cells in Systemic Lupus Erythematosus,” published in the Journal of Immunology Research, researchers summarized the role of a specific class of immune cells – natural killer T (NKT) cells – highlighting their potential as a new therapeutic target for systemic lupus erythematosus (SLE).